epcoritamab Epkinly
Selected indexed studies
- ** (, 2024) [PMID:39652694]
- Epcoritamab (Epkinly) for diffuse large B-cell lymphoma (DLBCL). (Med Lett Drugs Ther, 2023) [PMID:37339097]
- ** (, 2024) [PMID:39088680]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Epcoritamab: First Approval. (2023) pubmed
- Epcoritamab. (2006) pubmed
- Antibodies to watch in 2024. (2024) pubmed
- PMID:39652694 (2024) pubmed
- Epcoritamab (Epkinly) for diffuse large B-cell lymphoma (DLBCL). (2023) pubmed
- PMID:39088680 (2024) pubmed
- Epcoritamab-bysp (Epkinly) - A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma. (2023) pubmed
- [Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly(®) subcutaneous injection ) for malignant lymphoma]. (2024) pubmed
- Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience. (2025) pubmed
- Glofitamab (Columvi) for diffuse large B-cell lymphoma. (2023) pubmed